An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

A Multicenter, Open-Label Extension Study of the Long-Term Safety of Vonaprument (ANX007) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07807969

Acronym

AiiM OLE

Enrollment

605

Registered

2026-09-08

Start date

2026-09-30

Completion date

2029-07-31

Last updated

2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geographic Atrophy

Brief summary

The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.

Interventions

DRUGVonaprument

Form: solution for injection; Route of Administration: IVT injection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.

Exclusion criteria

* Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.

Design outcomes

Primary

Measure	Time frame
Number of Participants with Treatment Emergent Adverse Events	Through Month 24

Countries

United States

Contacts

CONTACTStudy Coordinator

clinicaltrials@annexonbio.com650-822-5500

STUDY_DIRECTORClinical Trials

Annexon, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026